<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ArQule Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/arqule-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ARQL) Company News for January 18, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416</link>
		<comments>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416#comments</comments>
		<pubDate>Wed, 18 Jan 2012 20:42:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Blackbaud Inc]]></category>
		<category><![CDATA[BLKB]]></category>
		<category><![CDATA[ISTA]]></category>
		<category><![CDATA[ISTA Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Valeant Pharmaceuticals International]]></category>
		<category><![CDATA[Venoco Inc]]></category>
		<category><![CDATA[VQ]]></category>
		<category><![CDATA[VRX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90416</guid>
		<description><![CDATA[•    Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company&#8217;s experimental treatment for liver cancer reported a positive outcome in its Phase II trial •    Share prices of discount carrier Sprint Airlines Inc. (NASDAQ:SAVE) declined 5.53% after the company announced plans to sell 11 million shares in a secondary offering •    Global provider of software Blackbaud Inc. (NASDAQ:BLKB) will buy fund raising software maker Convio Inc. (NASDAQ:CNVO) for $16 per share. Following the news, shares of Convio rocketed up 48% to close at $15.89 a share •    ISTA Pharmaceuticals Inc.’s shares (NASDAQ:ISTA) gained 13.07% after Valeant Pharmaceuticals International Inc. (NYSE:VRX) increased its hostile-takeover bid for ISTA to $7.50 a share •    Shares of natural gas firm Venoco Inc. (NYSE:VQ) surged 29.91% to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/18/arql-company-news-for-january-18-2012-corporate-summary/90416/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARRY) Array BioPharma Sees Positive Results for ARRY-380</title>
		<link>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765</link>
		<comments>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765#comments</comments>
		<pubDate>Tue, 15 Dec 2009 01:21:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Laboratories & Research]]></category>
		<category><![CDATA[ARQL]]></category>
		<category><![CDATA[ArQule Inc]]></category>
		<category><![CDATA[Array BioPharma]]></category>
		<category><![CDATA[ARRY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22765</guid>
		<description><![CDATA[Recently, Array BioPharma Inc. (ARRY) announced positive interim results on its inhibitor, ARRY-380, from an early-stage, open-label, multiple dose trial in patients with advanced cancer. The company presented the results at the 2009 San Antonio Breast Cancer Symposium. The study is designed to evaluate the safety, tolerability and pharmacokinetics of ARRY-380 following daily oral administration to patients suffering from advanced cancer. The candidate, which has been effective in preclinical models of human breast cancer resulting in significant anti-tumor activity, is a selective, orally-active ErbB-2 inhibitor being evaluated by Array for cancer indications. ErbB-2 is a receptor kinase target that has been found to be over-expressed in breast cancer as well as other cancers like gastric and ovarian cancers. The interim results revealed that ARRY-380 showed evidence of tumor regression in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/14/arry-array-biopharma-sees-positive-results-for-arry-380/22765/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

